Roche to launch laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients - Seite 2

The test will be another addition to the comprehensive Roche diagnostic portfolio of solutions to help healthcare systems combat COVID-19 through testing in the laboratory and at the point of care. These solutions include both tests to detect an acute SARS-CoV-2 infection and tests measuring the body’s immune response upon infection or vaccination. The following table provides an overview of Roche’s current COVID-19 test portfolio for the detection of an acute SARS-CoV-2 infection or immune response:

	Detection of acute infections (SARS-CoV-2 PCR or Antigen)	Detection of immune response (SARS-CoV-2 Antibodies)
Laboratory setting	cobas SARS-CoV-2 Test cobas SARS-CoV-2 & Influenza A/B Test NEW: Elecsys SARS-CoV-2 Antigen Test	Elecsys Anti-SARS-CoV-2 (N)4 immunoassay Elecsys Anti-SARS-CoV-2 S5 Immunoassay*
Point of Care setting (near patient)	SARS-CoV-2 Rapid Antigen Test* cobas Liat SARS-CoV-2 Test	SARS-CoV-2 Rapid Antibody Test*

*currently only available in CE markets

For more information, please also refer to the following infographic: 3 Factors that decide on the appropriate SARS-CoV-2 Test.

About the Elecsys SARS-CoV-2 Antigen test
Roche’s Elecsys SARS-CoV-2 Antigen test is an immunoassay intended for the qualitative detection of a specific antigen of SARS-CoV-2 present in the respiratory tract including nasopharynx and oropharynx. The Elecsys SARS-CoV-2 Antigen test is performed by healthcare professionals and could be used as an alternative or in conjunction with PCR testing. This is highly beneficial where reliable laboratory PCR testing is not available or where there are challenges in testing capacity. A positive result with the Elecsys SARS-CoV-2 Antigen test most likely indicates an active SARS-CoV-2 infection. A negative result may require to be confirmed with a PCR test or repeated (antigen test) after one to two days, if other clinical indications point to a SARS-CoV-2 infection. Performance evaluations around sensitivity and specificity of the test are ongoing and will be shared at the time of launch.